| 臺大學術典藏 |
2022-02-21T03:52:37Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; JIH-HSIANG LEE; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 國立成功大學 |
2022 |
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Na�ve Patients with�EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
|
Tu, H.-Y.;Feng, J.;Shi, M.;Zhao, J.;Wang, Y.;Chang, J.;Wang, J.;Cheng, Y.;Zhu, J.;Tan, E.-H.;Li, K.;Zhang, Y.;Lee, V.;Yang, C.-T.;Su, W.-C.;Lam, D.C.-L.;Srinivasa, B.J.;Rajappa, S.;Ho, C.-L.;Lam, K.C.;Hu, Y.;Bondarde, S.A.;Liu, X.;Tian, Y.;Xue, Z.;Cseh, A.;Huang, D.C.-L.;Zhou, C.;Wu, Y.-L. |
| 臺大學術典藏 |
2021-07-13T06:04:35Z |
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
|
Soh S.X.; Siddiqui F.J.; Allen J.C.; Kim G.W.; Lee J.C.; Yatabe Y.; Soda M.; Mano H.; Soo R.A.; Chin T.-M.; Ebi H.; Yano S.; Matsuo K.; Niu X.; Lu S.; Isobe K.; LEE JIH-HSIANG; Yang J.C.; Zhao M.; Zhou C.; Lee J.-K.; Lee S.-H.; Lee J.Y.; Ahn M.-J.; Tan T.J.; Tan D.S.; Tan E.-H.; Ong S.T.; Lim W.-T. |
| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N. |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
|
Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer
|
Hensing T; Lee C; Gupta N; Pradhan R; Qian J; Qin Q; Scappaticci F.A; Ricker J.L; Carlson D.M; Soo R.A.; Tan E.-H;Goss G.D;Salgia R;Besse B;Gandara D.R;Hanna N.H;Chih-Hsin Yang;Thertulien R;Wertheim M;Mazieres J;Hensing T;Lee C;Gupta N;Pradhan R;Qian J;Qin Q;Scappaticci F.A;Ricker J.L;Carlson D.M;Soo R.A.; Tan E.-H; Goss G.D; Salgia R; Besse B; Gandara D.R; Hanna N.H; CHIH-HSIN YANG; Thertulien R; Wertheim M; Mazieres J |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
|
Chih-Hsin Yang;Lorence R.M;Cong X.J;Shahidi M;Chao T.-Y;Tan E.-H;Crino L;Heo D.S;Sun Y;Wang M;Su W.-C;Zhou C;Kim S.-W;Park K;Chen Y.-M;Cadranel J;Hirsh V;Miller V.A; Miller V.A; Hirsh V; Cadranel J; Chen Y.-M; Park K; Kim S.-W; Zhou C; Su W.-C; Wang M; Sun Y; Heo D.S; Crino L; Tan E.-H; Chao T.-Y; Shahidi M; Cong X.J; Lorence R.M; CHIH-HSIN YANG |
